The SUM-102PT cell line was the first line that we established from cells from a primary breast cancer. The patient was originally thought to have locally advanced breast cancer based on imaging studies, but following biopsy and modified radical mastectomy, it was determined that the patient had extensive intraductal breast carcinoma. As a result, this cell line has many characteristics of normal mammary epithelial cells including a dependence on EGF for proliferation. The cells are wild-type for P53 but they do exhibit a common driving mutation in the PIK3CA oncogene. Thus, both in their behaviors and in their genome, these cells resemble early stage breast cancer.
Okay, let’s delve more deeply into the SUM-102 cell line.
- Characteristics of the patient specimen from which SUM-102 was derived
- Narrative Summary of the SUM-102 cell line
- The KEGG canonical pathways enriched with data from our genome-scale shRNA screen
- Point mutations in the SUM-102 cell line that appear in COSMIC
- The functional-druggable signature for SUM-102 cells
- Bibliography of published papers in which SUM-102 cells were used
- SUM-102 Blog page
Back to the SUM cell line Gateway Page
